Publication

MT-103 Micromet/MedImmune.

Cheadle, Eleanor J
Citations
Altmetric:
Abstract
Micromet AG and Medlmmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia.
Authors
Cheadle, Eleanor J
Affiliation
Paterson Institute for Cancer Research, Department of Medical Oncology, Wilmslow Road, Manchester M204BX, UK. Echeadle@picr.man.ac.uk
Description
Date
2006-02
Publisher
Collections
All Paterson Institute for Cancer Research
Show all metadata
Keywords
Type
Article
Citation
MT-103 Micromet/MedImmune. 2006, 8 (1):62-8 Curr. Opin. Mol. Ther.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/72697
Embedded videos